On July 16, 2025, Citigroup initiated coverage on WAVE Life Sciences (WVE, Financial), marking a significant development for the biotechnology company. The coverage was announced by Citigroup analyst Samantha Semenkow, who set a price target of USD 16.00 for WVE.
This initiation comes with a 'Buy' rating, providing a positive signal to investors regarding the potential performance of WAVE Life Sciences (WVE, Financial) in the market. The announcement reflects Citigroup's confidence in the company's future prospects and could influence investor sentiment.
The price target of USD 16.00 indicates the expected performance level as per Citigroup's assessment. It is important to note that this is a new coverage and thus does not have any prior price target or rating for comparison.
Investors and stakeholders in WAVE Life Sciences (WVE, Financial) will be keenly observing how this new coverage by Citigroup could impact the company's stock performance in the coming months.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 12 analysts, the average target price for WAVE Life Sciences Ltd (WVE, Financial) is $20.33 with a high estimate of $36.00 and a low estimate of $9.00. The average target implies an upside of 163.73% from the current price of $7.71. More detailed estimate data can be found on the WAVE Life Sciences Ltd (WVE) Forecast page.
Based on the consensus recommendation from 13 brokerage firms, WAVE Life Sciences Ltd's (WVE, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for WAVE Life Sciences Ltd (WVE, Financial) in one year is $3.38, suggesting a downside of 56.16% from the current price of $7.71. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the WAVE Life Sciences Ltd (WVE) Summary page.
